to genuine and needy passengers taking into account factors like status of he passengers travelling, nature of urgency like Government duty, bereavement, sickness etc. This criteria is followed regularly.

Medical Supplies to Primary Health Centres

939. SHRI GEORGE FERNANDES: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state the steps taken by the Government to provide adequate medical supplies and drugs to the hospitals particularly to primary health centres in various States, State-wise?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRIMATI D.K. THARA DEVI SIDDHARTHA): The Central Government, under the National Family Welfare Programme, provide Central assistance to the States for the purchase of medicines at the rate of Rs. 2,000/- per annum per sub-centre. As regards Primary Health Centres and hospitals, the medicines and other supplies are provided by the State Governments Certain medcines are also provided to the States free cost, like anti-TB drugs , anti-Leprosy drugs, drugs and vaccines for Maternal and Child Health-Care programme etc.

Sale of Banned Drugs

940. SHRI SHANKARRAO D. KALE: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether some drugs have been banned by W.H.O. and Indian Government;

(b) if so, the details thereof;

(c) whether these drugs are being sold in the market; and

(d) if so, the reasons therefor and preventive measures proposes to be taken by the Government in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRIMATI D.K. THARA DEVI SIDDHARTHA):(a) to (d). W.H.O. has so far intimated that some countries at different period of time have preferred to withdraw 44 drugs. Out of these 44 drugs, 26 drugs were never approved for marketing in the country. 11 drugs were banned and 7 were allowed for continued marketing with 'cautions' in some cases in consultation with experts and expert bodies like Indian Council of Medical Research.

The names of drugs banned by Government of India and the names of drugs allowed for continued marketing in consultation with experts along with the reasons is given in the Statement attached.